HighGravityDataEdwards Lifesciences — Jul 23, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001099800-26-000038
Showing in the filing
Adjusted EPS
“$0.71 to $0.77”
Period
Q3 FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 16
Total company sales growth (constant currency) for FY2026
“10% to 11%”
TAVR sales growth (constant currency) for FY2026
“8% to 9%”
TMTT product group sales for FY2026
“$760 to $780 million”
Adjusted EPS for FY2026
“$2.95 to $3.05”
Adjusted EPS growth at midpoint for FY2026
“17% at midpoint”
Total company sales growth target, longer term for the long term
“approximately 10% total company sales growth, on average”
Gross profit margin for FY2026
“at the lower end of its full-year 78% to 79%”
Gross profit margin for FY2026
“lower end of its full-year 78% to 79% gross margin guidance”
R&D expense as a percentage of sales for FY2026
“approximately 17%”
Operating profit margin for FY2026
“high end of the company’s original 28% to 29% guidance range”
Constant currency operating margin expansion for FY2026
“approximately 150 basis points”
Effective tax rate, excluding special items for FY2026
“at the high end of its previous range of 16% to 19%”
Total company sales for FY2026
“$6.6 billion to $6.9 billion”
TAVR sales for FY2026
“$4.75 billion to $5.0 billion”
Total sales for Q3 FY2026
“between $1.63 and $1.71 billion”
Adjusted EPS for Q3 FY2026
“$0.71 to $0.77”
Exhibit 99.1 · the passage around this item
… earlier in the release
Edwards is also reaffirming adjusted EPS guidance of $2.95 to $3.05, despite now assuming the company’s effective tax rate will be at the high end of the original 16% to 19% range. For the third quarter of 2026, the company projects total sales to be between $1.63 and $1.71 billion and adjusted EPS of $0.71 to $0.77. 4 About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. Conference Call and Webcast Information The company will be hosting a conference call today at 2:00 p.m. PT to discuss its second quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com or www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “pro
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.